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BACKGROUND 
The knee is the largest synovial joint in the body and is a common cause of lower-limb 
disability in patients over the age of 60.1 One of the most common ailments affecting the knee is 
osteoarthritis, an inflammatory process that leads to pain and altered joint function.2,3  
Osteoarthritis (OA) of the knee affects a large number of Americans and is a common cause of 
disability in older adults.1,4  The prevalence of arthritis in the U.S. is high with 29.3% of persons 
aged 45-64 and 49.6% of persons over 65 reporting a doctor-diagnosed arthritis.5  It is estimated 
that by the year 2030,  the number of people over 65 with osteoarthritis will reach more than 70 
billion.6 This high prevalence combined with the potential of knee osteoarthritis to lead to 
permanent disability places a large burden on the healthcare system.   
Osteoarthritis was once thought of as a “wear and tear” process but over the years, 
medical research has shown that the pathogenesis of OA is multifactorial and includes 
biomechanical factors, proinflammatory mediators, and proteases.3  Progressive destruction of 
joint cartilage in regions prone to maximal joint loading, leads to an increase in chondrocyte 
activity.  Chondrocytes maintain joint cartilage through a variety of anabolic and catabolic 
activities.  The upregulation of chondrocyte activity leads to an increase in the production of 
proinflammatory cytokines and proteases, which ultimately leads to matrix degradation.3 
Damage to the extracellular matrix leads to cartilage loss and OA symptoms including pain, 
swelling, grinding, catching and locking, all of which are suggestive of internal derangement of 
the knee caused by cartilage damage and bony fragments.6  Sclerosis of the bone, osteophyte 
formation, and synovial inflammation are also important characteristics of OA.3  OA of the knee 
is classified based on its etiology as either primary or secondary.  Primary knee OA is idiopathic 
meaning there is no known cause while secondary knee OA can result from previous surgery, 
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previous trauma, congenital malformations, or even metabolic (ex: Rickets, chondrocalcinosis, 
etc.) or endocrine (ex: hyperparathyroidism, acromegaly, etc.) disorders.2  
Modern advances in healthcare are allowing patients to live longer and as a result, the 
number of patients suffering from osteoarthritis will only continue to increase.1,2  As the number 
or patients suffering from OA increases, so will the burden on physicians and advanced practice 
providers (APPs) to care for these patients.  Therefore, physicians and APPs should make 
themselves aware of the various modalities that are available to patients to help them manage 
their symptoms.  While one approach or modality might work for one patient, it may not work 
for the next and so it is vital that we offer each patient an individualized treatment plan.  
Treatment plans should focus on each patient’s current symptoms, their normal activity level, 
and the outcomes they hope to achieve.  Patient-centered outcomes include decreased pain, fewer 
limitations in their daily life, and less morning stiffness.  The definitive treatment of knee OA is 
total knee arthroplasty (TKA) or total joint replacement.  TKA is indicated only in patients with 
advanced OA when conservative treatment has been tried without success.2  The purpose of this 
paper is to discuss the non-surgical management of knee OA and to compare stem cell injections 
vs. platelet-rich plasma injections to corticosteroid or hyaluronic acid injections in decreasing 
pain and improving function in patients over the age of 60 with knee osteoarthritis.   
 
GENERAL APPROACH TO THE PATIENT WITH KNEE OSTEOARTHRITIS 
   History 
The European League Against Rheumatism (EULAR) published a set of 
recommendations in 2013 for patients with hip and knee osteoarthritis and included in their 
recommendations are guidelines for the initial assessment of patients with knee OA.  They 
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recommend that the initial assessment should include “the person’s physical status, activities of 
daily living, participation, mood and health education needs, health beliefs, and motivation to 
self-manage”.1  Patients with knee osteoarthritis will typically present to their primary care 
physician with complaints of pain, joint swelling, joint stiffness, a decrease in range of motion, 
and/or stiffness upon first awakening in the morning.7 Patients will often complain of pain with 
the initiation of movement and an increased sensitivity to cold and/or damp weather.2  
Mechanical symptoms such as swelling, grinding, catching, or locking are suggestive of 
damaged cartilage or bony fragments that may produce severe limitations on range of motion.6  
As the disease progresses, patients begin to lose active range of motion, their pain becomes 
constant, and they have significant impairment in their ability to walk.2,3,4  These symptoms often 
lead to disability and limit a patient’s participation in their activities of daily living.1  A personal 
history of high-impact activities such as sports, genetic factors, gender, and one’s occupational 
history factor in to an individual’s risk of developing osteoarthritis.2,5,8  Additional risk factors 
for the development of knee OA include race/ethnicity, obesity, history of prior injury/surgery, 
physical activity, and mechanical factors.9,10  
   Physical Exam 
When initially evaluating a patient with possible knee OA it is important to follow the 
basic components of any physical exam including inspection, palpation, range of motion, 
neurovascular status and strength testing.  A noticeable limp may be appreciated during gait 
analysis.  Swelling of the knee, joint crepitus, and joint line tenderness are common physical 
exam findings in patients with knee OA.6  Range of motion and strength testing may be limited 
secondary to pain.  Special tests such as the Anterior Drawer, Lachman, and Valgus and Varus 
stress tests are useful in determining ligamentous stability and help rule out ligamentous injury as 
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a cause of a painful and acutely inflamed knee.  McMurray and Appley Compression tests are 
helpful in evaluating for meniscus tear and should also be included in the initial assessment.2  
   Laboratory and Radiographic Findings  
Arthrocentesis of the knee joint is necessary to rule out infection in patients presenting 
with an acute effusion and painful knee.  The synovial fluid should be sent for analysis to rule 
out other potential causes of arthritis of the knee (rheumatoid arthritis, gout, Pseudogout, 
infectious arthritis, etc.).6  Radiographs of the knee, both anterior-posterior and lateral views are 
the initial test of choice in diagnosing knee OA.  Common radiographic findings include 
narrowing of the joint space, osteophyte formation, and subchondral sclerosis and cysts.11  
Radiographs can also be used to stage the disease and follow the progression of disease over 
time.  A patient’s symptoms combined with their physical exam findings and radiographic 
evidence can be used to stage the disease process and attempt to correlate the disease to a typical 
course.2  Staging of knee osteoarthritis is based on the staging system of Kellgren and Lawrence 
where stage 0 is no abnormality and stage 4 is a combination of joint destruction, obliterated 
joint space, subchondral cysts, and a subluxed position (Table 1).2  Figures 1-2 are examples of a 
patient with stage 3 osteoarthritis of the right knee and stage 4 osteoarthritis on the left knee from 
multiple views.   
Table 1:  The staging of osteoarthritis of the knee after Kellgren and Lawrence 
Stage 0: No abnormality 
Stage 1:  Incipient osteoarthritis: beginning of osteophyte formation on eminences 
Stage 2: Moderate joint space narrowing, moderate subchondral sclerosis 
Stage 3: > 50% joint space narrowing, rounded femoral condyle, extensive subchondral sclerosis, extensive 
osteophyte formation 
Stage 4: Joint destruction, obliterated joint space, subchondral cysts in the tibial head and femoral condyle, subluxed 
position 
 
Adapted from Michael J, Schluter-Brust K, and Eysel P.  The epidemiology, etiology, diagnosis, and treatment of osteoarthritis of the knee.  Dtsch Arztebl Int. 2010; 107(9): 152-162. 
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Treatment options for knee osteoarthritis are extensive but most guidelines recommend 
starting with a non-pharmacological approach such as: 1) education and self-management; 2) 
exercise and weight loss; 3) assistive devices; and 4) complimentary integrative medicine (CIM) 
approaches.12,13  Common CIM approaches include massage and acupuncture.  Once patients 
have exhausted non-pharmacological approaches, their treatment can be augmented with 
pharmacologic management.  First-line pharmacologic management of OA is acetaminophen 
followed by topical NSAIDs, oral NSAIDS, and other agents (capsaicin and tramadol).12  Other 
pharmacologic agents include intra-articular corticosteroids, hyaluronic acid, platelet-rich 
plasma, and stem cell injections.12,13  This section will focus on the various non-pharmacologic, 
pharmacologic and intra-articular injections (corticosteroids and hyaluronic acid) as well as the 
evolving role of regenerative medicine injections (platelet-rich plasma and mesenchymal stem 
cells) in the treatment of knee osteoarthritis. 
 
Figure 1: Bilateral AP view of a 74 y.o. female 
seen in clinic with stage III knee OA on the 
right and stage IV knee OA on the left.  Note 
the extreme narrowing of the joint space, 
osteophyte formation and subchondral sclerosis.   
Figure 2: Lateral view of a 74 y.o. female seen in 
clinic with stage IV knee OA on the left.  Note the 
complete destruction of the tibio-femoral joint and 
the subchondral sclerosis.  Also of note is the 
osteophyte formation at the proximal pole of the 
patella as well as the subchondral sclerosis along 
the posterior aspect of the patella.  
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   Non-pharmacologic Treatment Options 
Conservative management is the first step in treating patients with knee OA and includes 
patient education, lifestyle modifications, weight loss in certain patient populations, and self-
management of symptoms. Patient education is crucial in helping patients understand the disease 
process associated with knee OA and allows them to decrease or eliminate potentially damaging 
activities that could speed up the disease process.2,12–15  According to the 2014 Osteoarthritis 
Research Society International (OARSI) guidelines for the non-surgical management of knee 
OA, patients suffering from chronic musculoskeletal pain showed moderate benefit in decreasing 
pain and disability by participating in self-management programs.13 Interventions aimed at 
promoting weight loss are among the initial recommendations in obese patients for the treatment 
of osteoarthritis.10  According to a systematic review conducted in 2014 by Nelson, Allen, 
Golightly, Goode, and Jordan seven guidelines regarding weight loss in patients with hip or knee 
OA were evaluated.  Of those 7 guidelines, 5 gave strong recommendations in favor of weight 
loss for patients with knee OA.12  A systematic review and meta-analysis from 2007 showed that 
a ten percent reduction in body weight in obese individuals led to reduction in pain and disability 
as well as the reduction of multiple risk factors for knee OA.16 
Manual therapy is another important component in the non-pharmacologic management 
of knee OA.  Varying manual therapy techniques are used to decrease pain and improve 
function.17 A randomized controlled trial from 2008 looked at the effect of manual therapy on 
pain associated with knee OA.15  43 patients ages 45-70 were randomly allocated to either the 
intervention or control group.  The intervention group received treatments consisting of 
myofascial mobilization and manipulation techniques 3 times per week for 2 consecutive weeks 
while the control group received manual contact without the application of the forces required 
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for the mobilization and manipulations.  After completing the two weeks of treatment, the 
intervention group reported an improvement in pain compared to the control group, which 
reported no change in symptoms.15 The manual therapy techniques allow for stretching of the 
patellofemoral joint capsule, which decreases restriction allowing for greater joint mobility and a 
decrease in pain.  Other studies have also looked at the effect of manual therapy on OA 
symptoms and found that manual therapy works to improve patient’s symptoms.  By decreasing 
the amount of pain the patient is in allows the patient to participate more readily in rehabilitation 
programs and daily activities.18,19 
Aerobic exercise and strength training play a pivotal role in the treatment of knee OA.  
Multiple systematic reviews 7,12 and a critical narrative review from 2016 20 all make strong 
recommendations in favor of including both water- and land-based exercise and strength training 
in the management of OA of the knee.  The purpose of rehabilitation for treating knee 
osteoarthritis is to improve range of motion, strengthen the muscles around the joint, improve 
proprioception and increase aerobic capacity.20,21 Aerobic exercise can be either water- or land-
based and should be implemented at a level that is consistent with the patient’s current level of 
exercise tolerance with a gradual progression.  Multiple studies have examined various types of 
exercise to determine if one type of exercise or exercise program was superior to the others in 
improving the symptoms of knee OA.1,10,12,13,15,16,20,22 These studies compared weight-bearing to 
non-weight-bearing, water-based to land-based, and group versus individual programs.  The 
overwhelming consensus was that exercise, no matter the form, is strongly recommended for 
patients with knee OA.1,10,12,13,15,16,20,22 In fact, recommendations from the European League 
Against Rheumatism (EULAR) published in 2013 states that “the mode of delivery of exercise 
education and use of pools or other facilities should be selected according both to the preference 
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of the person and local availability”.1  As for the frequency, duration, and intensity of the 
exercise programs, these should also be individualized to the patient but allow for gradual 
progression over time.1  A major benefit of exercise in the management of knee OA is that many 
forms of exercise are inexpensive, making it available to all patients regardless of insurance 
benefits and socioeconomic status. 
Studies have also looked at the efficacy of bracing and other assistive devices for patients 
with knee OA.  Devices such as orthotics, cushioned heels, or wedges are thought to work by 
unloading the mechanical stress of the knee and therefore relieve pain and improve joint 
function.2  Knee braces such as either valgus or varus unloader braces for medial and lateral knee 
OA respectively are recommended by the OARSI guidelines based on data from a 2011 
systematic review.12,13,23 The systematic review found that knee braces were effective in 
decreasing pain, stiffness, and the number of doses of NSAIDS patients were taking.  Patients 
also showed improvement in proprioception and physical function as well as the amount of 
condylar separation achieved by the brace.23  The American Academy of Orthopaedic Surgeons 
(AAOS) were unable to recommend for or against the use of valgus directing force braces 
(medial unloader brace) due to a lack of compelling evidence whether in favor of or against 
unloader braces.24  In regards to medial and lateral heel wedges, the OARSI guidelines 
recommended in favor of their use if directed by an appropriate specialist.13  This 
recommendation was made in spite of conflicting evidence from two randomized controlled 
trails.  A randomized controlled trial from 2011 found that patients experienced no relief in 
symptoms or improvement in function while wearing the wedged insoles.25  The second 
randomized controlled trial conducted in 2010 recommended the wedged insoles as an 
alternative to the unloader knee brace in patients with medial compartment knee OA.26  
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However, the AAOS recommended against their use in patients with medial knee OA based on 
the results of five studies; all of which showed no significant improvement in pain or physical 
function.24  The OARSI guidelines also recommend the use of a cane or walking stick in patients 
with knee OA as it could help decrease pain and possibly improve quality of life.  However, they 
strongly encourage further research in this area to confirm this recommendation.13  
   Pharmacologic Treatment Options 
Pharmacologic modalities continue to play a significant role in the treatment of 
osteoarthritis of the knee and are mainly aimed at decreasing pain and inflammation in order to 
improve function and allow patients to return to their normal daily activities.  Acetaminophen 
continues to be considered first-line in the treatment of knee OA; it is inexpensive and an 
effective analgesic with a more favorable side-effect profile compared to NSAIDs.12,27,28   
Acetaminophen works to inhibit the production of prostaglandins in the brain and spinal cord.  
Common side effects include renal and hepatic toxicity, elevated alkaline phosphatase, elevated 
bilirubin, and hypersensitivity reactions.  Doses greater than 4 g/day or concurrent alcohol use 
further increase a patient’s risk for hepatotoxicity.27 Acetaminophen is initially administered on 
an as needed basis but as the severity of OA worsens patients may require scheduled doses in 
order to reach adequate pain relief.  Recommended doses of acetaminophen are 325 mg every 4 
to 6 hours or 1000 mg (1 g) every 6 to 8 hours with a max dose of 4000 mg per day.27  Patients 
with inadequate relief from acetaminophen may not be taking a sufficient dose for the 
appropriate amount of time.  Patients are recommended to take up to 4 g per day (in divided 
doses) for 4 to 6 weeks in order to achieve a sufficient trial.27  The OARSI guidelines 
recommend in favor of the use of acetaminophen for knee OA in individuals without relevant co-
morbid conditions.13  The AAOS guidelines were the only guidelines where acetaminophen was 
Non-Operative Management of Knee Osteoarthritis  	 11	
not recommended as a first-line analgesic.  They were unable to recommend for or against the 
use of acetaminophen based on inconclusive evidence24.  The American College of 
Rheumatology (ACR) makes a conditional recommendation in favor of the use of acetaminophen 
initially for the management of knee OA.21  Before patients are started on an acetaminophen 
regimen, a careful history and review of current medications is essential to reduce the risk of 
adverse effects and unintentional acetaminophen overdose.27  Patients with chronic liver disease 
can still use acetaminophen but require more frequent monitoring. 
 For patients who fail to experience relief in symptoms after an adequate trial of 
acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs) can be used.21 Topical 
NSAIDs minimize systemic exposure seen with oral agents but are only appropriate in patients 
with superficial joint OA (hand, knee).12,13,21,27 In the United States, diclofenac is the only topical 
NSAID available.  While topical NSAIDs have a decreased risk for GI side effects they pose an 
increased risk of dermatitis, pruritis, and phototoxicity.27  According to the ACR 
recommendations from 2012, topical NSAIDs are preferred over oral agents in patients 75 years 
of age or older.21  For patients who fail to respond to topical NSAIDs or suffer from OA of 
deeper joints such as the hip, oral NSAIDs should be used.21,27  NSAIDS are also a reasonable 
first-line therapy for patients with moderate-to-severe OA.27  NSAIDs work by inhibiting both 
they cyclooxygenase enzymes (COX-1 and COX-2) that are responsible for synthesizing 
prostaglandins.27 They are frequently associated with gastrointestinal (GI) side effects such as 
nausea, dyspepsia, abdominal pain, diarrhea, peptic ulcer disease, and bleeding.27,29  For patients 
who experience GI side effects with NSAID use or those using them for the chronic management 
of knee OA, a proton pump inhibitor (PPI) can be added.21 
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Other common side effects associated with NSAID use include cardiovascular (CV) side 
effects such as stroke or myocardial infarction and renal impairment.  Patients with existing 
glomerular disease, renal insufficiency, hypercalcemia, heart failure, or cirrhosis or patients with 
true volume depletion are at increased risk for acute renal failure with the use of NSAIDs.29  
Since the use of NSAIDs can lead to acute kidney injury (AKI), acute interstitial nephritis (AIN), 
nephrotic syndrome, and papillary necrosis, their use should be limited in the aforementioned 
patient populations and in patients with decreased glomerular filtration rate (GFR).30  NSAIDs 
should be avoided completely in patients with a GFR less than 60 mL/min/1.73 m2.21,27,30 
Selective NSAIDs (ex. celecoxib) have a lower GI side effect profile but are associated with an 
increased risk for CV side effects.  NSAIDS can interfere with the anti-platelet effects of aspirin, 
and in patients with known cardiovascular disease they are associated with an increased risk of 
adverse cardiovascular events such as death, myocardial infarction (MI), heart failure, and 
stroke.20,27,31 
Patients respond differently to the various types of oral NSAIDs and therefore may have 
to try multiple agents before finding the NSAID that works best for them.  Dosing also varies 
widely between the different classes of NSAIDs and clinicians should consult current guidelines 
for appropriate dosing recommendations.27  Clinicians should take into account the patient’s 
preference, previous response to NSAIDs, frequency or dosing, and history of comorbid 
conditions when deciding in favor of or against any particular agent.27  Patients should also be 
educated that while they may experience pain relief within hours of starting the NSAID, it can 
take up to two to three weeks for the anti-inflammatory affect.  Therefore, clinicians should 
recommend that the patient continue the NSAID for at least 3 weeks in the absence of any 
adverse effects, in order to achieve an adequate trial.27  Of the available NSAIDS, naproxen is 
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considered to have the lowest risk for adverse cardiovascular events and is should therefore be 
the first-line agent in patients with a history of cardiovascular disease.   
The AAOS strongly recommends the use of either topical or oral NSAIDs for patients 
with knee OA.24  According to the OARSI guidelines, non-selective and selective NSAIDs are 
recommended in patients without comorbid conditions.8  The concomitant use of a PPI is also 
recommended in patients with moderate to high risk of adverse GI effects or the presence of 
comorbid conditions.13   Topical NSAIDs are recommended in patients with knee-only OA.  
They are not recommended in patients with multiple joint OA.13 The ACR recommends that 
topical or oral NSAIDs be used if a patient fails to have a satisfactory response to 
acetaminophen.  They too advocate for the addition of a PPI for patients who require chronic 
NSAID use.21 
 If patients continue to remain refractory to treatment after adequate trials of 
acetaminophen and NSAIDs, tramadol is a reasonable next step.  Although tramadol is a weak 
opiod, it is still considered a controlled substance.4  It works by inhibiting the reuptake of 
serotonin and norepinephrine to achieve its analgesic effects.  It has no effect however on the 
inflammatory process that contributes to the pathogenesis of OA.27  Tramadol can be used as a 
single agent or it can be used to augment a patient’s current regimen of acetaminophen or 
NSAIDs.  Common side effects associated with tramadol include dizziness, vertigo, nausea, 
vomiting, constipation, and lethargy.32  Concomitant use of tramadol and antidepressants has 
been found to increase a patient’s risk of seizure.27    A systematic review of the guidelines and 
recommendations published in 2014 recommend that tramadol should only be considered in 
patients refractory to other pharmacological alternatives.12  The AAOS strongly recommends the 
use of tramadol in the treatment of patients with symptomatic knee OA.24  The ACR 
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recommends the use of tramadol for patients 75 years and older in who the use of NSAIDs is not 
recommended.20  The OARSI guidelines do not separate low-potency opioids from traditional 
opioids and therefore conclude that the use of opioids in the long-term treatment of OA has 
limited usefulness.13   
Potent opioids such as oxycodone, hydromorphone, morphine, and transdermal fentanyl 
patches are only recommended in patients with comorbid conditions that prevent the use of 
NSAIDs or in patients with grade 4 OA in whom total joint replacement is not an option.27,32  
When initiating opioids, clinicians should start at the lowest possible dose and in combination 
with other non-opioid therapies (non-pharmacological therapies, acetaminophen, or NSAIDs).27  
Potent opioids have a similar side effect profile as tramadol with the addition of sedation and 
respiratory depression.  A systematic analytic review from 2016 compared the effects of orals 
NSAIDs to opioids in the treatment of knee OA.  They found that opioids provide similar 
analgesic effects as NSAIDs and should only be used when all other treatments have failed.4  
Before prescribing opioids, clinicians should conduct a thorough history and physical exam as 
well as ensure that previous non-opioid therapy has failed.27  The ACR had no recommendation 
regarding the use of opioids in the treatment of OA21 and the AAOS could neither recommend 
for or against their use due to inconclusive evidence.24 
   Intra-articular Injections 
Intra-articular (IA) corticosteroid injections have been a mainstay in the treatment of knee 
osteoarthritis for many years despite inconclusive data to support their use.12  IA corticosteroids 
work to provide pain relief and decrease inflammation by inhibiting the synthesis of 
prostaglandins and decreasing collagenase activity, respectively.33  Their use is typically 
indicated when patients have failed adequate trials of acetaminophen and NSAIDs.10,34 IA 
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corticosteroids are considered to have multiple advantages over systemic corticosteroids 
including increased bioavailability, decreased systemic exposure, and less adverse effects.34  
These injections can more directly target the pathophysiology associated with OA while 
maximizing efficacy and decreasing drug cost.34,35 Triamcinolone preparations are the most 
commonly used and are approved by the United States Food and Drug Administration (US 
FDA).35 Although IA corticosteroid injections are considered relatively safe, they do carry a risk 
of pain, swelling, or infection at the site of injection as well as systemic hyperglycemia.10,35  
Patients typically experience pain relief and improvement in other associated symptoms for up to 
4 weeks after the inection.34  There is concern among physicians and APPs that prolonged use of 
IA corticosteroids can have adverse effects on articular cartilage and potentially accelerate the 
progression of the disease.  Therefore most physicians and APPs recommend limiting the use of 
IA corticosteroids to 3-4 injections in any given joint per year.34,35     
Studies over the years that have looked at the efficacy of using intra-articular 
corticosteroid injections have inconclusive results.  A randomized clinical trial (RCT) conducted 
between 2011 and 2015 compared the efficacy of intra-articular triamcinolone versus saline in 
the treatment of symptomatic knee osteoarthritis.36  Patients enrolled in this study received an 
injection of either triamcinolone or saline every 3 months over the course of 2 years.  Results 
from the RCT showed a significant increase in cartilage volume loss and no significant decrease 
in pain in the group of patients receiving triamcinolone injections compared to the control group 
who received injections of saline.36  These results should raise the question to physicians and 
APPs alike as to whether intra-articular corticosteroid injections have a role in the treatment of 
knee osteoarthritis.  A 2015 Cochrane review of intra-articular corticosteroids for the treatment 
of knee OA found that patients experienced a moderate improvement in pain and a small 
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improvement in physical function.  Unfortunately the authors found the quality of evidence to be 
low and the results inconclusive.37 The OARSI guidelines recommend the use of intra-articular 
corticosteroid injections for the treatment of knee OA based on two systematic reviews (SRs) 
that showed a short-term clinically significant decrease in pain.13  The AAOS were unable to 
recommend for or against the use of intra-articular corticosteroids “due to a lack of compelling 
evidence that has resulted in unclear balance between benefits and potential harm”.24  The ACR 
conditionally recommends the use of intra-articular corticosteroid injections in the initial 
management of patients with symptomatic knee OA.21    
 Hyaluronic acid is a naturally occurring glycosaminoglycan in normal, healthy joint fluid 
and provides shock absorption, joint lubrication, and energy dissipation.27,38–40  IA administration 
of hyaluronic acid, also known as viscosupplementation has been a common modality in the 
treatment of knee OA since its approval by the US FDA in 2001.35  The use of IA hyaluronic 
acid has been reported to increase chondrocyte proliferation and decrease chondrocyte apoptosis 
which is thought to slow the progression of disease.34,35  Similarly to IA corticosteroids, 
viscosupplementation is commonly used in patients who have not had satisfactory relief from 
acetaminophen or NSAIDs.34  There are currently seven different formulations approved by the 
US FDA and administration varies from 1 to 5 weekly injections.34  Although they are widely 
used, there remains a division of opinion regarding their efficacy and role in the treatment of 
knee OA. 
 A systematic review of overlapping meta-analyses from 2015 found that IA hyaluronic 
injections are a safe and viable treatment option for the patients with knee OA and their effects 
are long-term, lasting up to 26 weeks.38  Their inspection of 14 different meta-analyses 
confirmed the hypothesis that IA hyaluronic acid provides significant improvement in pain and 
Non-Operative Management of Knee Osteoarthritis  	 17	
function.38  A 2009 systematic review and meta-analysis found that IA corticosteroids are more 
effective in the short-term (up to 4 weeks) while IA hyaluronic acid is a more effective long-term 
(8 weeks or more) modality.40  An article from July 2017 compared the effectiveness of IA 
hyaluronic acid and corticosteroid injections in delaying the time to surgery in patients with knee 
OA.  The authors found that there was no significant difference in the risk for surgery between 
the two groups and their results could not support the use of IA hyaluronic acid in the treatment 
of knee OA.39  A Cochrane review from 2010 found viscosupplementation to be an effective 
treatment for knee OA and that its effects on pain and function were superior to placebos.41  The 
same review found viscosupplementation to have more prolonged effects than IA corticosteroids 
and based on their results supported the use of IA hyaluronic acid in the treatment of knee OA.41  
The OARSI guidelines were uncertain in their recommendation on the use of IA hyaluronic acid 
in the treatment of knee OA based on inconsistent conclusions and conflicting results.13  The 
ACR had no recommendation regarding the use of IA hyaluronic injections and the AAOS could 
not recommend the use of IA hyaluronic acid.21,24  The AAOS based their recommendation on 
the lack of efficacy from the results of 14 studies that assessed the use of IA hyaluronic acid.24  
   Regenerative Medicine Intra-articular Injections 
As evidenced by the information above, the focus of current treatment modalities, 
whether they are pharmacological or non-pharmacological, has been on augmenting pain control 
and decreasing inflammation.  Regenerative medicine injections such as platelet-rich plasma 
(PRP) and mesenchymal stem cell (MSC) injections were initially thought to have the potential 
to reverse or correct the underlying disease process associated with OA.  This would be an 
appealing alternative to the goals of the more traditional modalities such as rehabilitation, oral 
agents (Tylenol, NSAIDS, etc.), or even corticosteroid or hyaluronic acid injections.     
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Platelet-rich plasma (PRP) is an autologous (from self) blood product derived from whole 
blood that has been centrifuged to produce a heavily concentrated number of platelets above an 
individual’s baseline.42  PRP has been used for several years in certain dental procedures and has 
also been found to play a role in the treatment of soft tissue lesions such as chronic ulcers, 
tendonopathies, and fasciitis.43,44 The growth factors that are released from the platelets have 
been shown to promote chondrogenesis and mesenchymal stem cell proliferation, increase anti-
inflammatory mediators, and decrease proinflammatory mediators through various pathways.45  
Although PRP injections are widely used in the treatment of knee osteoarthritis there remains a 
lack of concrete evidence in the literature to support its role in the treatment of knee OA.   
A systematic review from 2013 concluded that “multiple sequential intra-articular PRP 
injections may have beneficial effects in the treatment of adult patients with mild to moderate 
knee OA at approximately 6 months”.42  In a systematic review and meta-analysis published in 
2015 by Laudy, Bakker, Rekers, and Moen that reviewed 5 RCTs and 5 non-randomized trials 
the authors concluded that PRP injections are more effective in reducing pain in patients with 
OA of the knee when compared to placebo injections.46  However, the level of evidence 
supporting this conclusion was limited due to a high risk of bias.  The authors also concluded 
that PRP injections have a superior effect on pain associated with knee OA when compared to 
HA injections.  There was also a statistically significant difference between PRP and HA 
injections in improving physical function at both 6 months (MD -16.50; 95% CI -22.20 to -
10.80) and 48 weeks (MD -17.00; 95% CI -22.35 to -11.65) .46  Results from a RCT published in 
2015 did not show any significant difference in the use of PRP injections over HA injections in 
the treatment of patients with knee OA.47   
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The AAOS were unable to recommend in favor of the use of PRP injections in the 
treatment of knee OA base on inconclusive evidence and recommend that practitioners use 
clinical judgment in deciding whether or not to use PRP injections in the treatment of patients 
with symptomatic knee OA that has failed other treatment modalities.  They also recommend 
that practitioners continue to seek out new research that could help clarify the role of PRP 
injections in the treatment of knee OA.24  The ACR and OARSI do not consider PRP injections 
in knee OA treatment in their current guidelines.35 
Mesenchymal stem cells (MSCs) are immunosuppressive cells that are found in 
abundance in various types of adult tissue such as bone marrow, adipose, umbilical cord 
tissue/blood, synovium, and periosteum.48,49  MSCs were first characterized by Dr. Alexander 
Friedenstein over forty years ago and are suggested to have a fundamental role in repairing and 
regenerating tissue.50  Over the past decade, they have continued to attract attention as a 
promising therapeutic modality for knee OA.49 The ability of MSCs to differentiate into many 
cell types such as bone and/or cartilage allows them to have the potential to revolutionize the 
treatment of cartilage defects associated with osteoarthritis.51,52  In addition to the ability to 
differentiate into a variety of cell types, MSCs also play a significant role in the 1) control and 
modulation of inflammation;  2) inhibition of programed cell death (apoptosis); 3) stimulation of 
the endogenous proliferation and repair of cells; and 4) expansion of blood flow to joints.49,53  
The overall goal of MSCs in the treatment of knee OA is to aid in the self-healing process of the 
cartilage, ultimately resulting in symptom relief.53 
Research in the area of MSCs as a treatment modality for knee OA is still relatively new 
and some controversy remains regarding the safest and most efficacious use of MSCs.  MSCs 
can be autologous, obtained from self, or allogeneic, obtained from a donor.  While autologous 
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stem cells would be considered less likely to be rejected by the host’s immune system, the 
process of harvesting the cells from the patient and allowing time for cell expansion prior to 
injection or implantation makes the procedure both expensive and time-consuming.54  A 
randomized controlled trial from 2015 looked at the efficacy of treating knee OA with allogeneic 
bone marrow MSCs.54  Thirty patients (17 females and 13 males) with chronic knee OA that had 
been unsuccessfully treated with conventional methods for at least 6 months were enrolled in the 
study.  The control group received injections of hyaluronic acid while the experimental group 
received allogeneic bone marrow MSC injections.  The authors’ results found that the use of 
allogeneic MSCs for the treatment of knee OA are safe, feasible, and effective.  The group 
receiving allogeneic MSCs reported a 38-42% improvement in their pain while the hyaluronic 
acid group (control group) reported only a 10-14% improvement in pain.54   
Other areas of debate in current research include harvest sites, mechanism of delivery, 
whether or not to use a scaffold such as platelet-rich plasma, and the number of cells needed per 
treatment to reach therapeutic effects.  Adult MSCs can be harvested from either adipose tissue, 
bone marrow, or umbilical cord tissue or blood but the best source remains unclear.48–52  Bone 
marrow has traditionally been the preferred harvest site but recent research has discovered that 
the number of MSCs obtained from bone marrow aspirates is insufficient.50  The use of adipose 
tissue as a harvest site is becoming increasingly more common due to the ease of the lipoaspirate 
procedure and the abundance of cells obtained.50,55 A randomized controlled pilot study is 
currently in the preliminary stages of comparing the results of arthroscopic microfracture alone 
to microfracture combined with postoperative injection of adipose derived MSC therapy in the 
treatment of isolated chondral defects.55  The authors hypothesize that the postoperative MSC 
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injections will lead to better cartilage formation and in the long-term improve the efficacy in the 
prevention of secondary knee OA.55   
The most effective delivery method of the MSCs also continues to be under evaluation.  
MSCs can either be injected into the joint or they can be implanted using a technique similar to 
autologous chondrocyte transplantation (ACT).50  Results from current preclinical trials that are 
evaluating the efficacy of the injection method have shown that intra-articular injections of 
MSCs are improving function.  However, these same trials have shown inconsistent results when 
evaluating whether or not intra-articular MSC injections have any effect on cartilage 
restoration.50  A comparative matched-pair analysis from 2015 evaluated the effectiveness of the 
injection of MSCs compared to the implantation of MSCs for knee OA.  The study enrolled 14 
men and 26 women and divided them into two separate groups.  One group received arthroscopic 
MSC injection and the other group underwent arthroscopic MSC implantation.  The major 
finding of the study showed that the patients receiving MSC implantation showed greater 
improvement (p value = .041) in cartilage regeneration at second-look arthroscopic surgery 
compared to those receiving MSC injection.53  The authors concluded that “a single simple 
injection of MSCs is insufficient for the repair of damaged articular cartilage…because of 
limited cell retention and survival at the target site”.53  
Another topic of debate in the use of MSCs is whether or not to use a scaffold such as 
platelet-rich plasma (PRP) or hyaluronic acid (HA).  As discussed earlier, the platelets in PRP 
solutions have a high concentration of growth factors, peptide hormones, cytokines, and fibrin.  
It is hypothesized that the growth factors in PRP solutions have the ability to up-regulate MSCs 
leading to increased expression of type II collagen and the reduction of chondrocyte apoptosis.50  
Hyaluronic acid has also been used as a carrier method and preclinical results have shown that 
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HA combined with MSCs enhances the migration of synovial cells and chondrocytes to the 
location of the cartilage defect.  HA may also work to enhance the adherence of MSCs to the 
cartilage defect itself.50  Several articles make mention of the uncertainty of the number of MSCs 
to reach a therapeutic dose but the authors don't attempt to address this in their current 
research.49,53 According to Wolfsstadt et al., “the optimal dose, frequency, timing, and number of 
injections remains unclear”.49 
 
CONCLUSION 
 Osteoarthritis (OA) is a progressive condition that leads to the degeneration of cartilage 
and severely inhibits the patient’s level of function.  OA is not caused by a single, isolated event, 
but instead is the cumulative result of aging and trauma.  Symptomatic knee OA affects as many 
as 10% of men and 13% of women over the age of 60 and will only increase as the population 
ages.  Symptoms associated with knee OA lead to substantial disability and increasing medical 
costs.9  The high prevalence combined with the fact that patients are living longer means that the 
burden on the health care system to care for patients with OA will only continue to grow.  It is 
imperative that clinicians educate themselves on the various treatment modalities available in 
order to develop an individualized treatment plan for their patients that is both efficacious and 
low cost.     
Current treatment options are aimed at slowing the progression of the disease and 
delaying total joint arthroplasty.  The goal of conservative treatment is to decrease pain and 
improve function.  This is achieved through a combination of non-pharmacological and 
pharmacological approaches.  Patient education and therapeutic exercise are both strongly 
recommended throughout various guidelines and therefor should be implemented in all patients 
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suffering from knee OA.1,12,13  Although studies have looked extensively into the efficacy of 
rehabilitation exercises, controversy remains over the type of exercise, effective dosage and/or 
frequency, duration, and intensity.  More extensive studies are warranted to further evaluate the 
most effective modality, intensity, duration, and frequency.  Dr. Maura Iverson recommends that 
exercise programs be viewed similarly to medications; that each modality has its own associated 
risks and benefits.7  The overall consensus of the various guidelines is that physical exercise and 
rehabilitation are effective in decreasing pain and improving function.  Exercise programs should 
be initiated on a individualized basis based on the patient’s exercise tolerance and previous level 
of function.   
Pharmacologic modalities include acetaminophen, NSAIDs, weak opioids, and intra-
articular injections such as corticosteroids and hyaluronic acid.  The guidelines have a strong 
consensus that pharmacologic modalities be initiated in a stepwise approach with the initial drug 
of choice being acetaminophen.  If patients fail to obtain relief from their current pharmacologic 
modality, the guidelines recommend confirming that the patient has received an adequate trial 
(therapeutic dose for the recommended period of time) before escalating therapy.  Although 
popular in the treatment of knee OA, the efficacy of intra-articular (IA) injections such as 
corticosteroids and hyaluronic acid continue to remain under debate.  The guidelines vary in their 
recommendations for IA corticosteroid injections with some organizations recommending in 
favor of IA corticosteroids and some recommending neither in favor nor against their use.13,21,24  
There appears to be consensus among the guidelines for the use of hyaluronic acid (HA) 
injections with the majority of organizations being unable to recommend for or against its use in 
the treatment of knee OA.13,21,24  These organizations base their recommendations on 
inconsistent conclusions and conflicting results.13  There is clear consensus across all guidelines 
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that total joint arthroplasty should only be performed when conservative treatment has failed.2 
Regenerative medicine injections such as PRP and MSCs have recently been suggested to 
potentially reverse or correct the underling disease process associated with knee osteoarthritis.  
The thought behind these injections is that they potentially allow for remodeling of the joint, 
which allows for healing.  This leads to improvement in pain and function; ultimately allowing 
the patient to delay or even avoid surgery altogether.10   PRP injections for the treatment of knee 
OA have been gaining popularity in recent years.   Recent RCTs have found that PRP injections 
are effective in decreasing the amount of pain associated with knee OA but the evidence for 
supporting these findings comes with a high risk of bias.46  Another RCT from 2015 showed no 
benefit in using PRP injections for the treatment of knee OA when compared to HA injections.47  
The collective results from recent studies regarding the role of PRP injections in the treatment of 
knee OA is inconclusive.  PRP injections could very well be a viable treatment option for 
patients with knee OA but more studies are needed.  Current RCTs that are attempting to 
evaluate the efficacy of PRP injections are limited by their small sample sizes, short follow-up 
periods and the large amount of variability in collection and application of PRP.43  There is a 
great need for RCTs with larger sample sizes, longer periods of observation, and standardization 
of treatment protocols.  Standardizing treatment protocols would help to eliminate heterogeneity 
and help to establish more evidence-based guidelines for clinicians.  PRP treatment protocols 
should include standardized preparation techniques (number of centrifugations, concentrations of 
platelets and white blood cells, use of an activator, etc.), number of injections, volume to inject, 
length of interval between injections, and the location of injection.  Establishing a standard 
protocol would help to establish more consistent results in future trials.  
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Another promising modality in the treatment of knee OA is the use of mesenchymal stem 
cell (MSC) injections.  Unfortunately, the majority of current research in this area has been 
completed using animal subjects and design methods of current studies remains highly variable.  
Similarly to PRP injections, the lack of a standardized treatment protocol in the use of MSC 
injections hinders researchers ability to fully evaluate the potential role of MSCs in the treatment 
of knee OA.  Areas to address in such protocols include 1) autologous versus allogeneic MSCs; 
2) harvest site (bone marrow, adipose, or umbilical cord); 3) mechanism of delivery (injected vs. 
implanted); 4) use of a scaffold; and 5) the number of MSCs per treatment.   Perhaps one of the 
greatest areas of discord in current research is the mechanism of delivery of MSCs to the area of 
the chondral defect.  Whether it be injection or implantation, the delivery of MSCs to the site of 
the defect must be an extremely efficient one in order for MSCs to be a viable therapeutic option.  
Some researchers even argue that efficient delivery of MSCs to the site of the chondral defect is 
more important than the number of MSCs delivered to the site of the defect.53  Therefore, more 
studies on human subjects are needed to evaluate the efficacy of MSC intra-articular injections 
versus implantation. 
The role of regenerative medicine injections is certainly intriguing and has the potential 
to revolutionize the treatment of osteoarthritis.  Unfortunately, the overwhelming consensus is 
that there remains a plethora of uncertainty surrounding these injections and their safety and 
efficacy in the management of knee osteoarthritis.  The overwhelming consensus regarding the 
use of regenerative medicine injections is that more randomized controlled studies are needed.  
These studies should include larger subject populations and longer follow-up periods in order to 
fully evaluate the role of these injections in the treatment of knee OA.  
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APPENDIX 1: RESEARCH METHODS 
A PubMed search was completed using the key words stem cell injections, corticosteroid 
injections, platelet-rich plasma injections, and knee osteoarthritis.   Additional search terms 
included non-pharmacological treatment of osteoarthritis and treatment guidelines for knee 
osteoarthritis.  An UpToDate search was also completed using the key words knee osteoarthritis. 
In order to obtain additional articles for this clinical review a reference search of the systematic 
reviews and treatment guidelines identified during the primary PubMed and UpToDate searches 
was used to identify additional pertinent articles.  
 
APPENDIX 2: RISK OF BIAS EVALUATION FOR INCLUDED RANDOMIZED 
CONTROLLED TRIASLS 
 
Table 2: Evaluation of bias for included randomized controlled trials 
Author (Date) Selection Bias Performance 
Bias 
Detection Bias Attrition Bias Reporting 
Bias 
Pollard et al. (2008) Moderate High Unclear Low Low 
Hameed et al. (2017) Moderate Moderate Unclear Low Low 
Deyle et al. (2000) Low Low Unclear Low Low 
Deyle et al. (2005) Low Low Unclear Low Low 
Bennell et al. (2011) Low Low Low Low Low 
Van Raaij et al. (2010) Low High High Low Low 
McAlindon et al. (2017) Low Low Low Low Low 
Filardo et al. (2015) Low Low Moderate Low Low 




APPENDIX 3: QUALITY OF EVIDENCE FOR INCLUDED COCHRANE REVIEWS  
 
Table 3: Quality of evidence for included Cochrane reviews 
Author (Date) Summary of Quality of Evidence 
Hari et al. (2015) Using GRADE analysis the authors graded the quality of evidence as low for all of their 
findings; meaning that they have little confidence in these results. The authors attributed this to 
being due to the results being, in general, highly discordant across studies and mainly based on 
small studies of low quality.  
Bellamy et al. (2010) Trials included in the systematic review were assessed separately by two reviewers for 
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APPENDIX 4: ANALYSIS OF SYSTEMATIC REVIEWS  
 
Table 4: Level of evidence among included systematic reviews 
Author (Date) Summary Statement Level of Evidence* 
Smith et al. (2016)4 In the evaluation of pain reduction in patients with OA treated with 
NSAIDs, less potent opioids, and potent opioids the mean reduction 
in WOMAC pain was comparable between the three classes.  
Ia 
Pas et al. (2017)8 Based upon the high risk of bias in all of the studies included in this 
review, there is no high level of evidence for stem cell therapy in the 
treatment of patients with knee OA. The authors do not recommend 
the use of stem cell therapy for patients with knee OA.  
Ia 
Nelson et al. (2014)12 An essential agreement on many recommendations for OA 
management was found in guidelines from various societies.  The 
authors concluded that the deficit is not in the lack of quality 
guidelines but in getting those guidelines disseminated and 
implemented in the primary care settings and other specialty settings.   
IV 
Larmer et al. (2014)14 Authors found that that within the guidelines for the management of 
knee OA, exercise and education were the most strongly 
recommended.  There is strong evidence to support the use of 
exercise, electrical-based therapy, equipment, education, diet and 
weight loss, manual therapy, and self-management.  
IV 
Christensen et al. (2007)16 Authors determined that physical disability could be improved by 
weight loss.  Overweight individuals should initiate a 10% reduction 
in body weight.  
Ia 
Jansen et al. (2011)22 Exercise therapy with manual joint mobilization helps decrease pain 
(effect size  0.69) compared to strength training (effect size 0.38) or 
exercise therapy (effect size (0.38) when used alone. 
Ia 
Raja et al. (2011)23 Despite heterogeneity in current studies and a lack of clinical trials, 
knee braces and foot orthoses have been shown to help decrease the 
level of stress transmitted though the medial compartment of the 
knee.  
Ib 
Campbell et al. (2015)38 Intra-articular viscosupplementation is a safe and viable treatment 
option for knee IA with effects that can last up to 26 weeks. 
Ia 
Bannuru et al. (2009)40 Intra-articular corticosteroids is more effective in the short term (up 
to 4 weeks) and intra-articular hyaluronic acid is more effective in the 
long term (4-26 weeks) 
Ia 
Khoshbin et al. (2013)42 When compared to hyaluronic acid or normal saline injections, 
multiple intra-articular PRP injections, when given in a sequence, 
may have beneficial effects in patients with mild to moderate knee 
OA beginning at approximately 6 months post-injection.  
Ia 
Meheux et al. (2016)45 Intra-articular PRP injections results in significant clinical 
improvement up to 12 weeks post-injection in patients with 
symptomatic knee OA. 
Ib 
Laudy et al. (2015)46 Intra-articular PRP injections are more effective in decreasing pain 
and improving function in patients with knee OA when compared to 
placebo and hyaluronic acid injections.  
Ia 
Xia et al. (2015)51 There is potential for MSC injections to have a significant effect on 
pain and potential benefit on physical function in patients with knee 
OA at 3, 12, and 24 months post-injection but the evidence is 
inconclusive.  
Ia 
*Level of Evidence: Ia = meta-analyses of randomized controlled trials (RCT); Ib = at least 1 RCT; IIa = at least 1 controlled trial 
(CT) without randomization); IIb = at least 1 type of quasi-experimental study; III = descriptive studies (comparative, correlation, or case-
control studies); IV = expert committee reports or opinions and or clinical experience of respected authorities. 
¶ Levels of evidence adapted from Fernandes L, Hagen KB, Bijlsma JWJ, et al. EULAR recommendations for the non-pharmacological core 
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